IncellDx

IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.

The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.

The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.

The deal covers IncellDx's portfolio of immune-oncology & oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells & immune cell subtypes.

The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.

The deal covers IncellDx's single-cell immune-oncology and oncology diagnostic products including its single-cell PD-L1 assay.

The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.

The kit uses a proprietary non-enzymatic method to prepare intact, single-cell suspensions from tissue in less than 10 minutes.

Single-cell RNA sequencing on thousands of tumor and surrounding cells from 19 melanoma samples revealed subsets of cells with apparent resistance potential.

Pages

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.